Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia (Q34044905)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia |
scientific article |
Statements
1 reference
Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia (English)
1 reference
Hagop M Kantarjian
1 reference
Giovanni Martinelli
1 reference
Aristoteles Giagounidis
1 reference
Jacques-Olivier Bay
1 reference
Elias J Jabbour
1 reference
Alfonso Quintás-Cardama
1 reference
Kiyoshi Ando
1 reference
Andrew Wei
1 reference
Stefanie Gröpper
1 reference
Cristina Papayannidis
1 reference
Kate Owen
1 reference
Laura Pike
1 reference
Nicola Schmitt
1 reference
Paul K Stockman
1 reference
SPARK-AML1 Investigators
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference